New shot for schizophrenia shows promise in early safety trial
NCT ID NCT06627413
First seen Apr 11, 2026 · Last updated Jun 13, 2026 · Updated 14 times
Summary
This early-stage study tested a long-acting injectable form of the drug lumateperone in 52 adults with stable schizophrenia or schizoaffective disorder. The goal was to see how the body processes the drug and whether it is safe and tolerable. Participants received a single shot, and researchers monitored drug levels and side effects over time.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SCHIZOPHRENIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Clinical Site 1
Marlton, New Jersey, 08053, United States
-
Clinical Site 2
Los Alamitos, California, 90720, United States
-
Clinical Site 3
Atlanta, Georgia, 30331, United States
-
Clinical Site 4
Decatur, Georgia, 30030, United States
Conditions
Explore the condition pages connected to this study.
Conditions inferred from the trial description
These were inferred from the trial's summary, not listed by the trial registrant.